Alzheimer’s Treatment First Administered in Canada: New Perfusion Study

Sharon Runge has ⁢become the first patient in Canada to receive an infusion‍ of lecanemab, a recently Health Canada-approved Alzheimer’s drug.

Dr. Sara Mitchell,a cognitive neurologist,explains,”This is a historic moment for people with Alzheimer’s and their families in Canada,as we’ve been able to intervene meaningfully in this disease.”

Canada is the last of the G7 nations to ⁢approve lecanemab, a monoclonal antibody that removes harmful ⁤amyloid plaques from the brain and has demonstrated a slowing of disease progression by ⁤approximately 30%. To delve into the‍ specifics, the drug aims to address a key pathological hallmark of Alzheimer’s.

“Long-term data⁣ now shows⁣ us that taking this medication for four years extends the period of ⁢independence by one year.”

– Dr. Sara Mitchell, cognitive neurologist

Across the country, individuals with Alzheimer’s are facing increasing ⁣dependence on loved ones. This medication⁢ offers the⁤ promise of ⁤prolonged independence. It’s important to note that while not a cure, lecanemab represents ⁤a meaningful step forward in managing the disease.

For Mr. Dallard, Ms. Runge’s husband, the newly approved drug offers hope that he and his wife will receive the most precious gift of all: time.

the availability of lecanemab marks a turning point in Alzheimer’s care in Canada,offering a new avenue for treatment and a potential extension of quality life for patients and their families. ‍This growth is part of a larger tapestry of ongoing research⁣ into Alzheimer’s disease.